Sarclisa (isatuximab or isatuximab-irfc) is a monoclonal antibody that’s used to treat a type of blood cancer called multiple myeloma. It helps stop the cancer from growing and spreading. Sarclisa (isatuximab) is given as an intravenous infusion through your vein (IV). It’s typically given together with two other medications to treat cancer. Sarclisa (isatuximab) might cause side effects such as infusion-related reactions, low white blood cell counts, and diarrhea.
Sarclisa (isatuximab) is an anti-CD38 monoclonal antibody. It specifically attaches to proteins called CD38 that are found on the surface of cells. Sarclisa (isatuximab) is able to attach only to cancer cells (like those of multiple myeloma) because they have more of this protein than healthy cells.
Once Sarclisa (isatuximab) attaches to CD38 on the cancer cells, it sends signals to the immune system to come attack it. Sometimes, the medication can attack the cell itself. This helps stop the cancer from growing and spreading.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
While Sarclisa (isatuximab) is a medication that’s used to treat cancer, it’s not considered chemotherapy. Traditional chemotherapy works by attacking and killing cells that are growing quickly. This includes both cancer and healthy cells. Sarclisa (isatuximab) is different because it’s a targeted therapy that only attacks cells with a certain protein called CD38. This allows Sarclisa (isatuximab) to be more specific in how it attacks multiple myeloma cancer cells.
Most people with multiple myeloma need to take an antiviral medication, such as acyclovir (Zovirax) or valacyclovir (Valtrex). This is to help prevent a viral infection called herpes zoster, which is the virus that causes shingles. Taking an antiviral medication during treatment is important. People with multiple myeloma, including those who take medications like Sarclisa (isatuximab), are at risk of serious infections (such as with herpes zoster) since they might have an immune system that can’t fight infections as well.
Typically, people who take Sarclisa (isatuximab) don’t lose their hair. If you notice any hair loss during treatment, talk to your provider because there can be other causes of hair loss.
How long you take Sarclisa (isatuximab) depends on several factors, such as how well the medication is working to treat your multiple myeloma and how well you tolerate its side effects. Your provider will determine how well Sarclisa (isatuximab) is working by regularly checking your lab test and scan results. Some side effects, such as tiredness and diarrhea, can be bothersome but usually aren’t serious. But others, such as a severe infusion reaction or a serious infection, might mean you have to pause or stop taking Sarclisa (isatuximab). Don’t stop taking the medication without first discussing it with your provider.
It depends on what other medications you’re taking with Sarclisa (isatuximab). Sarclisa (isatuximab) itself isn’t known to cause heart problems or make heart problems worse. But it’s sometimes given with another medication called Kyprolis (carfilzomib) that might. If you have heart problems and you’re not sure what other medications you’re taking with Sarclisa (isatuximab), talk to your provider.
Sarclisa (isatuximab) isn’t safe to take during pregnancy. Based on how this medication works, Sarclisa (isatuximab) can harm an unborn baby. For this reason, if you’re a woman who’s able to have children, you must use effective birth control while you’re taking Sarclisa (isatuximab) and for 5 months after the last dose.
Sarclisa (isatuximab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Many people have experienced an infusion-related reaction during treatment with Sarclisa (isatuximab). Most of the time, these reactions happened during the first treatment. Because of this, your first treatment will be given more slowly. To help prevent a reaction, your nurse will give you medications such as diphenhydramine (Benadryl) and acetaminophen (Tylenol). They’ll also closely watch for reactions during your infusion.
Symptoms of an infusion reaction related to Sarclisa (isatuximab) usually includes trouble breathing, cough, stuffy nose, and nausea. More seriously, infusion reactions can also cause swelling in the face and changes in blood pressure. If you have any symptoms of a reaction during your infusion, tell your nurse right away. Some people who have a reaction can still take Sarclisa (isatuximab). But sometimes, the reaction is severe and the medication must be permanently stopped.
People who take Sarclisa (isatuximab) commonly have low blood cell counts, particularly low white blood cells (also called neutropenia). White blood cells are an important part of your immune system. When they’re low, you might be at higher risk for serious and life-threatening infections.
Your provider will check your blood cell counts before every Sarclisa (isatuximab) treatment. They might prescribe other medications such as antibiotics or antivirals to protect you from serious infections.
It’s important to lower your risk of getting sick by washing your hands often and avoiding crowds. Check your temperature regularly, and call your provider right away if your temperature is 100.4 degrees Fahrenheit or higher.
Some people taking Sarclisa (isatuximab) developed a new cancer. In studies, skin cancers were the most commonly reported new cancer. But there were also a few cases of angiosarcoma (a rare cancer of the blood and lymph vessels) and a blood cancer called myelodysplastic syndrome. Your provider will monitor you for new signs and symptoms of cancer, especially skin cancers, while you’re taking Sarclisa (isatuximab).
Sometimes, people with multiple myeloma need certain tests to monitor their red blood cells (such as a Coombs test) or other tests to check for blood compatibility before they receive a blood transfusion. In addition to those found on cancer cells, Sarclisa (isatuximab) can attach to CD38 proteins found in low numbers on red blood cells. This can affect your test results; the lab result reading might say they’re abnormal when they’re in fact normal.
To account for this, the lab or blood bank takes extra steps to make sure they get the correct test results for you. Be sure everyone who’s taking care of you and performing any type of lab test knows that you’re taking Sarclisa (isatuximab). This helps them know that they need to take those extra steps to make sure your lab results are correct.
Based on animal studies, Sarclisa (isatuximab) might harm an unborn baby when it’s taken during pregnancy. Because of this risk, if you’re a woman who can have children, you should use birth control while taking Sarclisa (isatuximab) and for 5 months after the last dose. Let your provider know right away if you become pregnant while taking Sarclisa (isatuximab).
This medication is given as an intravenous (IV) infusion. The dose is based on your body weight.
The typical dose is 10 mg/kg of body weight given once a week for the first cycle (4 weeks). For the following cycles, the medication is given once every 2 weeks.